Open AccessThis article is
- freely available
Endogenous Matrix-Derived Inhibitors of Angiogenesis
Department of Surgery, Umea University Hospital, Umea University, SE-90185 Umea, Sweden
Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, Oulu, Finland
Department of Oncology, Institute of Medicine, Haukeland University Hospital, University of Bergen, Bergen, Norway
* Author to whom correspondence should be addressed.
Received: 10 August 2010; in revised form: 19 September 2010 / Accepted: 25 September 2010 / Published: 28 September 2010
Abstract: Endogenous inhibitors of angiogenesis are proteins or fragments of proteins that are formed in the body, which can inhibit the angiogenic process. These molecules can be found both in the circulation and sequestered in the extracellular matrix (ECM) surrounding cells. Many matrix-derived inhibitors of angiogenesis, such as endostatin, tumstatin, canstatin and arresten, are bioactive fragments of larger ECM molecules. These substances become released upon proteolysis of the ECM and the vascular basement membrane (VBM) by enzymes of the tumor microenvironment. Although the role of matrix-derived angiogenesis inhibitors is well studied in animal models of cancer, their role in human cancers is less established. In this review we discuss the current knowledge about these molecules and their potential use as cancer therapeutics and biomarkers.
Keywords: angiogenesis; extracellular matrix; collagen; cancer; therapy; biomarker
Citations to this Article
Cite This Article
MDPI and ACS Style
Sund, M.; Nyberg, P.; Eikesdal, H.P. Endogenous Matrix-Derived Inhibitors of Angiogenesis. Pharmaceuticals 2010, 3, 3021-3039.
Sund M, Nyberg P, Eikesdal HP. Endogenous Matrix-Derived Inhibitors of Angiogenesis. Pharmaceuticals. 2010; 3(10):3021-3039.
Sund, Malin; Nyberg, Pia; Eikesdal, Hans Petter. 2010. "Endogenous Matrix-Derived Inhibitors of Angiogenesis." Pharmaceuticals 3, no. 10: 3021-3039.